Monthly News Roundup: April 2017

Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and … Read More →

How Adaptive Trial-Friendly EDC Benefits Oncology

Adaptive clinical trial design in oncology research represents an intersection of two major industry trends. One of these is the current prevalence of cancer clinical trials. Last year, Clinical Leader cited a GBI Research report that declared oncology the largest therapeutic area in the pharmaceutical industry pipeline. And the promise of immunotherapy continues to galvanize … Read More →

Monthly News Roundup: March 2017

Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and … Read More →

Monthly News Roundup: January 2017

Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and … Read More →

What Does Immunotherapy Mean for Trial Design?

It has now been a year since we first posted about immunotherapy on this blog, and several years since the first FDA approval of an immunotherapy treatment for cancer. For anyone paying attention, it’s difficult to avoid the conclusion that immunotherapy is one of today’s hottest topics not only in oncology, but in healthcare at … Read More →

Adaptive Trials: Is Your Study Equipped to Adapt?

Imagine, for a moment, you’re a data manager overseeing a Phase I study. Your endpoints are set, your database built and deployed, and your data collected. Now it’s time to cross your fingers, unblind your database, and hope for favorable tolerability results for the dosage you established. To your dismay, you discover you’ve overestimated the … Read More →

Monthly News Roundup: October 2016

Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and … Read More →

The Horrors of Source Data Verification (infographic)

It was a cold, dark night. The researchers had been moving quickly and were ahead of schedule, unaware of the menace that haunted their clinic – until it struck! Now they’re trapped in the clinic, doomed to lose precious time and funding, prisoners of the specter known as Source Data Verification. This Halloween, we’re here … Read More →

Phase I in the Age of Precision Medicine and Patient Diversity

As clinical research evolves and becomes more refined, the industry is coming to acknowledge a simple truth: that everyone is different. A drug that works wonders for one individual may have little to no effect on, or even be detrimental to, another. Alternatively, the discovery that a treatment is ineffective or dangerous in a small … Read More →

Following Up on Industry Predictions

Late last December, Clinical Leader published an interview with Jonathan Zung, a 20-year pharma veteran who built his career at a number of major companies, including some who have collaborated with Medrio. In it, he offered some predictions as to which clinical research trends he expected to take off in the new year. As we … Read More →